Current and future treatments for Alzheimer’s disease
Top Cited Papers
- 15 October 2012
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 6 (1), 19-33
- https://doi.org/10.1177/1756285612461679
Abstract
Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as ‘disease-modifying’ drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials.Keywords
This publication has 79 references indexed in Scilit:
- New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsBritish Journal of Clinical Pharmacology, 2012
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- Developing β‐secretase inhibitors for treatment of Alzheimer’s diseaseJournal of Neurochemistry, 2011
- Disease-modifying treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders, 2011
- Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer's diseaseVaccine, 2010
- Amyloid-β immunisation for Alzheimer's diseaseThe Lancet Neurology, 2008
- Active and Passive Immunotherapy for Neurodegenerative DisordersAnnual Review of Neuroscience, 2008
- Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloidNeuroscience, 2007
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2006
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004